Using a single calibration curve with the anti-Xa chromogenic assay for monitoring heparin anticoagulation

Laboratory Medicine

Volumn 36, Issue 5, 2005, Pages 297-299

  McGlasson, David L ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CALIBRATION; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEPARINIZATION; HUMAN; MALE; PATIENT MONITORING; RECURRENT ABORTION;

EID: 17744399929     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/HYCDUCQTV8YN145Y     Document Type: Article

References (17)

1. Fristsma GA. Evaluation of hemostasis. In: Kodak BF (editor), Hematology: Clinical Principles and Applications. 2002; 738.
2. Adler BK. Unfractionated heparin and other antithrombin mediated anticoagulants. Clin Lab Sci. 2004;17:113-117.
3. Adcock DM, Krestin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. AJCP. 1997;107:105-110.
4. Adcock DM, Kessin DC, Marlar RA. Minimum volume requirements for routine coagulation testing: dependence on citrate concentration. AJCP. 1998;109:595-599.
5. Storbeck M, Johnson M, Hayward CPM. The effect of low molecular weight heparin on LA testing. Thromb Haemost. 1995;73:1271.
6. Castellone D. Coagulation do's and don'ts. Advance. 2004;13:50-53.
7. Jensen R, Fritsma GA. Preanalytical variables in the coagulation laboratory. Advance. 2000;9:90-94.
8. Castellone D. How to deliver quality results in the coagulation laboratory: Commonly asked questions. Lab Med. 2004;4:208-213.
9. Triplett D. Laboratory monitoring of heparin therapy. Hemoliance Times. 1997:2.
10. Werner M, Gallagher JV, Ballo MS, et al. Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions on heparin therapy. AJCP. 1994;102:237-241.
11. Olson JD. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy. Arch Path Lab Med. Special Reprint. 1998; 23.
12. NCCLS Document H21-A3. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays. 1998.
13. Evans EW, Turner K. Anti-factor Xa testing for monitoring heparin therapy. Clin Hemos Rev. 2000;14:8-9.
14. Canton MM. Introduction to thrombosis and anticoagulant therapy. In: Harmening DM (editor), Clinical Hematology and Fundamentals of Hemostasis 1997, 581.
15. Becton-Dickinson. Clinical White Paper. Evaluation of BD Vacutainer™ 2.7 ml glass CTAD (sodium citrate, theophylline, adenosine and dipyridamole) coagulation tube with normal donors, donors on oral anticoagulant therapy and I.V. anticoagulant. 2001 VS5816:1-6.
16. Meyers BJ, Plumhoff EA, Gastineau DA, et al. A heparin assay system capable of measuring unfractionated heparin and low molecular weight heparin using the same standard curve. Blood. 1998;92:Suppl 1:123b.
17. Gilbert M, Goret N, Roland Y, et al. Validity of the new STA®-Calibrator LMWH for assaying most commonly used LMWH preparations with STA®-Rotachrom® heparin. Throm and Haemost. 2001;86:Supplement 1.